H1614
Phase 2- Indications
- Group 3 pulmonary hypertension
Company intelligence / Profile preview
HALO Centers
Palo Alto, California, United Stateshalobiosciences.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Clinical-stage biotech developing first-in-class hyaluronan remodeling agents for pulmonary hypertension; lead candidate (H1614) in Phase 1 with focus on disease-modifying mechanism and ECM targeting in fibrotic/inflammatory conditions.
- Therapeutic areas
- PulmonologyCardiovascularGastroenterology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Stanford University (IP/licensing, foundational science)
Beyond the preview
Go deeper on HALO Centers.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HALO Centers.